Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.

Pediatric hematology and oncology - 1 Nov 2009

Ehsani Mohammad Ali, Hedayati-Asl Amir Abbas, Bagheri Alireza, Zeinali Syrus, Rashidi Armin

Abstract excerpt

BACKGROUND: Hydroxyurea (HU) may improve the symptoms in thalassemia patients by increasing gamma-globin chain expression. However, the efficacy of HU in beta-thalassemia intermedia (TI) is unclear. METHODS: The authors treated 16 transfusion-independent TI patients (8 males) aged 10.7 +/- 5.0 ye...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Globins
Share to beta-Thalassemia
Share to Blood Transfusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Fetal Hemoglobin

Share to Hemoglobins

Share to Hydroxyurea

Share to Remission Induction

Source

Identifiers

PMID: 19954365
DOI: 10.3109/08880010903271671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19954365-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.PMID 19954365Read ↗

Response to hydroxyurea therapy in beta-thalassemia.Semantic proximity Read ↗

Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.Semantic proximity Read ↗

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.Semantic proximity Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.Semantic proximity Read ↗

Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the XmnI Polymorphism.Semantic proximity Read ↗

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.Semantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

Do alpha deletions influence hydroxyurea response in thalassemia intermedia?Semantic proximity Read ↗

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.Semantic proximity Read ↗

Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.Semantic proximity Read ↗

Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.